Proposed consolidation of share capital (2824B)

TIDMNGG

RNS Number : 2824B

NextGen Group PLC

13 April 2012

NextGen Group Plc

Proposed consolidation of share capital

Further to the announcement on 2 April 2012 of a Notice of AGM, the Company wishes to draw shareholders' attention to the proposed resolution to consolidate the Company's ordinary shares (Resolution 6) and the explanation for this proposal which is also set out in the Notice of AGM. Should the resolution be passed, then every 500 ordinary shares of 0.1p will be consolidated into one new ordinary share of 50p. Further details are set out in the Notice of AGM which is available on the Company's website: www.nextgensciences.com.

ENDS

For further details please contact:

Klaus Rosenau

Chairman

NextGen Group

Tel: +49 (0)160 5516756

Barry McAleer PhD

CEO

NextGen Sciences Inc

Tel: +44 (0)7825 413 110

Nicola Marrin/Jonathan Wright (Nominated Adviser)

David Banks (Broker)

Tel: + 44 (0)20 7107 8000

Seymour Pierce Limited

Notes to Editors:

NextGen Group Plc (AIM: NGG) is a provider of biomarker services for pharmaceutical and biotech companies globally through its USA-based subsidiary, NextGen Sciences Inc and a developer of diagnostic markers and assays through its second US-based subsidiary, NextGen Sciences Dx. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients.

NextGen Sciences Inc is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Ann Arbor, Michigan, USA. NextGen Sciences' range of services, which include biomarker discovery, assay development, validation and testing are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.

NextGen Sciences Dx is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Boston, Massachusetts, USA. NextGen Sciences Dx utilises the expertise of NextGen Sciences Inc to discover biomarkers and develop assays for point-of-care diagnostics, to assist in patient treatment, for selection of patients for clinical trials and to aid decision-making on efficacy determination for therapeutic development.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGRGDSIUBBGDX

Nextgen (LSE:NGG)
過去株価チャート
から 5 2024 まで 6 2024